(PRGO) Perrigo - Ratings and Ratios

Perrigo Company plc (NYSE:PRGO) is a leading global provider of over-the-counter (OTC) health and wellness products, operating in the Americas, Europe, and internationally. The company is structured into two primary segments: Consumer Self-Care Americas and Consumer Self-Care International. Its product portfolio spans a wide range of categories, including upper respiratory solutions (cough suppressants, expectorants, sinus and allergy relief), nutrition products (infant formulas, nutritional beverages), digestive health products (antacids, anti-diarrheal, anti-heartburn), pain and sleep-aids (pain relievers, fever reducers), and oral care products (toothbrushes, floss, whitening products). Additionally, Perrigo offers healthy lifestyle products (smoking cessation, well-being), skin care products (dermatological care, scar management, lice treatment), womens health products (feminine hygiene, contraceptives), vitamins, minerals, and supplements, as well as rare diseases treatments and miscellaneous self-care products. The company markets its products under a diverse range of brands, including Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, and ellaOne. Perrigo also provides contract manufacturing services to its clients. Its distribution network includes retail drug, supermarket, and mass merchandise chains, e-commerce platforms, wholesalers, pharmacies, drug and grocery retailers, and para-pharmacies. Established in 1887 and headquartered in Dublin, Ireland, Perrigo Company plc was formerly known as Perrigo Company before adopting its current name in December 2013.

From a technical perspective, PRGO is currently trading at $25.22, below its 20-day SMA of $25.75 and 50-day SMA of $26.40, while remaining near its 200-day SMA of $26.11. The stocks Average True Range (ATR) of 0.91 indicates moderate volatility. Fundamentally, Perrigos market cap stands at $3.385 billion, with a forward P/E ratio of 8.24, suggesting potential undervaluation. However, the companys price-to-book (P/B) ratio of 0.78 and price-to-sales (P/S) ratio of 0.77 reflect its current valuation metrics. Despite these factors, the negative return on equity (RoE) of -3.87% raises concerns about profitability.

3-Month Forecast: Based on the provided data, PRGO is expected to face short-term headwinds due to its current price trending below key moving averages. The 20-day and 50-day SMAs are likely to act as resistance levels, potentially capping upside momentum. However, the forward P/E ratio of 8.24 suggests that the market may begin to price in future earnings growth, providing a floor for the stock. Volatility is expected to remain manageable, with the ATR of 0.91 indicating limited price swings. While the negative RoE may weigh on investor sentiment, the companys diversified product portfolio and strong market presence could support stability in the near term. Overall, PRGO is projected to trade in a range between $24.50 and $26.50 over the next three months, with downside risk tied to earnings performance and macroeconomic conditions.